ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO503

SGLT2 Inhibitor Ameliorates Smooth-Muscle Cell Proliferation via Endothelial Microparticles Stimulated by Indoxyl Sulfate

Session Information

  • Dialysis Vascular Access
    October 25, 2024 | Location: Exhibit Hall, Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Dialysis

  • 803 Dialysis: Vascular Access

Authors

  • Lee, Shina, Ewha Womens University Mokdong Hospital, Seoul, Korea (the Republic of)
  • Kim, Seung-Jung, Ewha Womens University Mokdong Hospital, Seoul, Korea (the Republic of)
Background

Endothelial microparticles (EMPs) are closely associated with vascular dysfunction. Recent research has revealed a link between SGLT2 inhibition and improved endothelial functions. We investigated the effects of SGLT2 inhibitors (SGLT2i) on EMP generation from indoxyl sulfate-stimulated endothelial cells and their impact on smooth muscle cell (SMC) proliferation.

Methods

We measured CD31+CD42-EMP counts by flow cytometry in supernatants of human umbilical vein endothelial cells (HUVECs) incubated with indoxyl sulfate. We examined the EMP responses to SGLT2i by incubating EMPs from indoxyl sulfate-stimulated HUVECs with or without SGLT2i.

Results

1. Indoxyl sulfate induced EMP release in HUVECs. 2. SGLT2i inhibited EMP generation induced by indoxyl sulfate. 3. The EMPs induced by indoxyl sulfate stimulated smooth muscle cell proliferation, and this effect was reversed by treatment with SGLT2i.

Conclusion

SGLT2 inhibitor ameliorates smooth muscle cell proliferation via endothelial microparticles stimulated by indoxyl sulfate. SGLT2i could be a treatment option for neointimal hyperplasia in vascular access stenosis.